Skip to content

Ananda Developments - Appointment of AQSE Corporate Adviser and Broker

Announcement provided by

Ananda Developments Plc · ANA

15/05/2023 07:00

Ananda Developments - Appointment of AQSE Corporate Adviser and Broker
RNS Number : 1527Z
Ananda Developments PLC
15 May 2023

12 May 2023


("Ananda" or the "Company")

Appointment of AQSE Corporate Adviser and Broker

Following the completion of the acquisition of MRX Global Limited and its wholly owned subsidiary MRX Medical Limited and raising of £427,400, the directors of Ananda are pleased to announce that SP Angel Corporate Finance LLP ("SP Angel") has been appointed as the Company's AQSE Corporate Adviser and sole Broker, with immediate effect.

SP Angel has a dedicated in-house healthcare research team and will release an Initiation Research Report on the Company in the coming weeks. As SP Angel acts as a NOMAD it would be able to support Ananda with a smooth transition to AIM at the appropriate time.

Ananda's CEO, Melissa Sturgess, commented: "Ananda's ambition to be a provider of cannabis-based medicines for the treatment of complex, chronic inflammatory pain conditions, places us firmly in the healthcare sector. We believe that working with the dedicated, experienced, and respected healthcare research and capital markets team at SP Angel will help us refine our story, expand our reach to a wider audience and prepare the company for bigger markets. I would also like to take this opportunity, on behalf of the Board, to thank Peterhouse for its support and guidance as our corporate adviser and broker since Ananda's listing in 2018."


The Directors of the Company accept responsibility for the contents of this announcement.



+44 (0)7463 686 497

Chief Executive Officer

Melissa Sturgess

Chief Operating Officer

Jeremy Sturgess-Smith


+44 (0)20 3470 0470

Corporate Finance

Richard Morrison

Harry Davies-Ball


Corporate Broking

Abigail Wayne

Rob Rees


About Ananda Developments

Ananda is an AQSE-listed medical cannabis company whose ambition is to be a leading provider of high-quality medical cannabis for the treatment of complex, chronic inflammatory pain conditions for the UK and international markets.

For more information, please visit:


Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

ANA announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal